Literature DB >> 27225465

Aromatase inhibitors and anti-synthetase syndrome.

Fabio Mascella1, Lorenzo Gianni2, Alessandra Affatato2, Manuela Fantini2.   

Abstract

Adjuvant therapy in postmenopausal women with endocrine-responsive breast cancer (BC) is actually centered on the use of anti-aromatase inhibitors (AI). Several reports, however, are emerging in literature associating the use of this drugs to rheumatic disorders. This case report describes the first case of anti-synthetase syndrome diagnosis after treatment with anti-estrogen agents in a patient with pre-existing rheumatoid arthritis.
© The Author(s) 2016.

Entities:  

Keywords:  anti-synthetase syndrome; aromatase inhibitors; rheumatoid arthritis

Mesh:

Substances:

Year:  2016        PMID: 27225465      PMCID: PMC5806753          DOI: 10.1177/0394632016651086

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  15 in total

Review 1.  Immunomodulatory effects of anti-estrogenic drugs.

Authors:  Amitabha Ray; Monica Ficek
Journal:  Acta Pharm       Date:  2012-06       Impact factor: 2.230

2.  Improvement in dermatomyositis rash associated with the use of antiestrogen medication.

Authors:  Danya Sereda; Victoria P Werth
Journal:  Arch Dermatol       Date:  2006-01

3.  Henoch-Schönlein purpura and aromatase inhibitors.

Authors:  Federico PELLEGRINI; Valentina ROSSI; Flavia FASSONE; Enzo CASTRACANE; Luca PERSEMOLI; Claudio ALTOBELLI; Paolo ASTORRE
Journal:  Eur J Dermatol       Date:  2009-06-15       Impact factor: 3.328

4.  Rheumatoid arthritis and aromatase inhibitors.

Authors:  Ewa Bertolini; Hélène Letho-Gyselinck; Clément Prati; Daniel Wendling
Journal:  Joint Bone Spine       Date:  2011-01       Impact factor: 4.929

Review 5.  American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.

Authors:  Harold J Burstein; Ann Alexis Prestrud; Jerome Seidenfeld; Holly Anderson; Thomas A Buchholz; Nancy E Davidson; Karen E Gelmon; Sharon H Giordano; Clifford A Hudis; Jennifer Malin; Eleftherios P Mamounas; Diana Rowden; Alexander J Solky; Maryfran R Sowers; Vered Stearns; Eric P Winer; Mark R Somerfield; Jennifer J Griggs
Journal:  J Clin Oncol       Date:  2010-07-12       Impact factor: 44.544

Review 6.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Authors:  Eitan Amir; Bostjan Seruga; Saroj Niraula; Lindsay Carlsson; Alberto Ocaña
Journal:  J Natl Cancer Inst       Date:  2011-07-09       Impact factor: 13.506

7.  The effect of antiestrogen agents on risk of autoimmune disorders in patients with breast cancer.

Authors:  Jason Y Chen; Stanley P Ballou
Journal:  J Rheumatol       Date:  2014-10-01       Impact factor: 4.666

Review 8.  Aromatase inhibitor-induced arthralgia: a review.

Authors:  P Niravath
Journal:  Ann Oncol       Date:  2013-03-06       Impact factor: 32.976

9.  Joint pain with aromatase inhibitors: abnormal frequency of Sjögren's syndrome.

Authors:  Michel Laroche; Séverine Borg; Slim Lassoued; Brigitte De Lafontan; Henri Roché
Journal:  J Rheumatol       Date:  2007-10-15       Impact factor: 4.666

10.  A paraneoplastic manifestation of metastatic breast cancer responding to endocrine therapy: a case report.

Authors:  Joanna P Wood; Andrew P Haynes; K L Cheung
Journal:  World J Surg Oncol       Date:  2008-12-16       Impact factor: 2.754

View more
  2 in total

Review 1.  Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.

Authors:  Sara Tenti; Nicola Giordano; Maurizio Cutolo; Fabio Giannini; Antonella Fioravanti
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 2.  Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects.

Authors:  Sara Tenti; Pierpaolo Correale; Sara Cheleschi; Antonella Fioravanti; Luigi Pirtoli
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.